Efficacy and safety of combination of nifuratel tablets with Baofukang suppository on treatment and recurrence of vaginitis in pregnancy

Abstract


 
 
 
 Purpose: To investigate the effect and safety of a combination of Nifuratel tablets and Baofukang suppository in the treatment and recurrence of vaginitis in pregnant patients.
 Methods: A retrospective analysis was carried out on 100 in-patients admitted between February 2019 and April 2020. They were randomly assigned to control and study groups, with 50 in each group. The control group received Baofukang suppository treatment, whilst the study group was treated with Nifuratel tablets in addition to Baofukang suppository. The two groups were compared with regard to treatment effectiveness, incidence of adverse reactions, recurrence at 1, 2 and 3 months post-treatment; time taken for disappearance of clinical symptoms, and levels of inflammatory factors 1 week after treatment. Moreover, Mental Status Scale in Non-Psychiatric Settings (MSSNS) score, and Quality of Life Index (QLI) score were compared between the groups.
 Results: The study group out-performed the control group with respect to treatment effectiveness and QLI score (p < 0.05). Patients in the study group had significantly lower incidence of adverse reactions, degree of recurrence at 1, 2 and 3 months post-treatment, time taken for disappearance of clinical symptoms, expression levels of inflammatory factors, and MSSNS score, when compared to those in control group (p < 0.05).
 Conclusion: Combined use of Nifuratel tablets and Baofukang suppository in the treatment of pregnant patients with vaginitis leads to significant treatment efficacy and safety, and reduced recurrence and expression levels of inflammatory factors in patients.